Industry Alliance Program - Highlighted CIRM-Catalyzed Spinouts

Quote mark

CIRM's support has been instrumental to our early successes and our ability to rapidly progress Forty Seven's CD47 antibody targeting approach with magrolimab. CIRM was an early collaborator in our clinical programs and it’s support was instrumental in helping us reach a point where we could become a part of Gilead and move forward with our research.”

Dr. Mark Chao, Co-Founder, Forty Seven, Inc.

HIGHLIGHTED CIRM-CATALYZED SPINOUTS

CIRM funding to California academic institutions has enabled the launch of more than 40 spinout companies, some of which are highlighted below.

PUBLIC

Click on logos below to learn more

Anti-CD47 Ab immunotherapies for cancer and blood disorders

CIRM Impact: Funded discovery and preclinical development of anti-CD47 antibody at Stanford, currently funding two Forty Seven Inc. clinical trials.

Partnering Highlights: $4.9B Gilead Acquisition

Forty Seven; https://www.gilead.com

CAR-T therapies for cancer and gene therapy for blood disorders

CIRM Impact: Funded discovery and preclinical development, and currently funding clinical trials, of multiple CAR-T therapies at City of Hope.

Partnering Highlights: $31.5M Public Offering (2019)

Gene therapies for immune disorders

CIRM Impact: Funding lead candidate ADA-SCID gene therapy clinical trial as well as X-CGD gene therapy trial.

Partnering Highlights: $225.5M IPO (2018)

Orchard Therapeutics; https://www.orchard-tx.com

Epigenetics research tools

CIRM Impact: Funded research in epigenetics at Stanford that enabled Epinomics launch.

Partnering Highlights: Acquired by 10X Genomics (2018)

Anti-ROR1 Ab immunotherapies for cancer

CIRM Impact: Funded discovery, preclinical and clinical development of anti-ROR1 Ab at UCSD, currently funding Oncternal’s clinical trial.

Partnering Highlights: Reverse Merger with GTX (2019)

Oncternal Therapeutics; http://www.oncternal.com

VENTURE-BACKED

Click on logos below to learn more

Gene therapies for various disease indications

CIRM Impact: Funded directed evolution of AAV research at UC Berkeley.

Partnering Highlights: $90M Series B (2018)

4D Molecular Therapeutics; https://www.4dmoleculartherapeutics.com

WNT-based therapies for bone regeneration

CIRM Impact: Funded discovery and preclinical development of WNT-based therapy at Stanford, currently funding Ankasa’s IND-enabling studies.

Partnering Highlights: $19M Venture Financing

Ankasa Regenerative Therapeutics; https://ankasaregenerativetherapeutics.com

iPSC-based cell therapy for Parkinson’s disease

CIRM Impact: Funded iPSC research and candidate discovery at Scripps.

Partnering Highlights: $70M Series A venture financing (2020)

Aspen Neuroscience; https://www.aspenneuroscience.com

iPSC-based T-cell immunotherapies for cancer

CIRM Impact: Funded technology platform development and candidate discovery at Stanford.

Partnering Highlights: $250M Series A financing (2019)

Century Therapeutics; https://www.centurytx.com

Ab-based bone marrow conditioning regimen

CIRM Impact: Funded discovery and preclinical development, and currently funding clinical trial, at Stanford.

Partnering Highlights: $50M Series A financing (2020)

Jasper Therapeutics; https://jaspertherapeutics.com

iPSC-based cancer vaccines & cell therapies for cardiovascular diseases

CIRM Impact: Funded candidate discovery research at Stanford.

Partnering Highlights: Funded by Leaps by Bayer (2019)

Khloris Biosciences; https://www.khlorisbiosciences.com

CRISPR-based RNA gene therapy

CIRM Impact: Funded technology platform development at UCSD

Partnering Highlights: $55M Series A financing (2019)

Magnetic particle imaging in living organisms

CIRM Impact: Funded technology platform development at UC Berkeley.

Partnering Highlights: Commercial

Neural cell therapies for neurological disorders

CIRM Impact: Funded research of stem cell-derived specialized neurons at UCSF, currently funding Neurona’s preclinical development of lead candidate for epilepsy.

Partnering Highlights: $28.5M Series A financing (2014); $20M Series B financing (2018); $43.5M Series C financing (2020)

Neurona Therapeutics; https://www.neuronatherapeutics.com

ESC-based tissue engineered patch for dry AMD

CIRM Impact: Funded candidate discovery and preclinical development at USC, UCSB & Caltech and RPT’s phase 1/2a clinical trial.

Partnering Highlights: Santen Pharma partnership (2017)

Regenerative Patch Technologies; https://regenerativepatch.com

In vivo gene therapy for cardiac diseases

CIRM Impact: Funded direct reprogramming and candidate discovery research at Gladstone.

Partnering Highlights: $92M Series B venture financing (2019)

Tenaya Therapeutics; https://www.tenayatherapeutics.com

Anti-ROR1 Ab based antibody drug conjugates for cancer

CIRM Impact: Funded Anti-ROR1 Ab discovery and development at UCSD.

Partnering Highlights: $58M Series A venture financing (2018)

PRIVATE

Click on logos below to learn more

Progenitor cell therapy for Retinitis Pigmentosa

CIRM Impact: Funded discovery and preclinical development at UCI, currently funding jCyte’s phase 2 clinical trials.

Partnering Highlights: $252M Santen Ex-US Licensing & Commercialization Agreement (2020)

Latest Press Releases

CIRM-funded research programs are helping turn stem cells into cures. Browse our press release archive below to find out the latest advances. For even more breaking news, visit our blog, The Stem Cellar.